Polycythemia vera (PV) is characterized by erythrocytosis, thrombocytosis, and/or leukocytosis with a broad-range of disease-related symptoms that impact the overall health and everyday quality of life of patients. The significant symptom burden seen in PV patients has been associated with loss of productivity and difficulties in the activities of daily living, defining a need for careful consideration of management strategies in these patients. The identification of the high frequency JAK2V617F mutation present in around 95% of all PV patients defined a molecular target for therapeutic intervention and mature data from initial clinical investigations with JAK inhibitors in PV are now being analyzed. This Expert Perspectives activity is a conversation between Drs. Srdan Verstovsek and Jason R. Gotlib highlighting the key take home messages from the “JAK Inhibitors for the Successful Management of Patients with Polycythemia Vera” symposium.
Earn accreditation for this activity at the following location:
[ Ссылка ]
© 2015 Imedex, LLC.
